Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies
- DOI
- 10.1007/s00392-025-02719-z
- Published
- 2025-08-04
- Container
- Clinical Research in Cardiology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s00392-025-02719-z,
title = {Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies},
author = {Klaus G. Parhofer and David Pittrow and Andreas L. Birkenfeld and Uwe Fraass and Bernd Hohenstein and Carsten Siegert and Jens Klotsche and Elisabeth Steinhagen-Thiessen and Stefan Dexl and Volker J. J. Schettler and Ulrich Laufs},
year = {2025},
journal = {Clinical Research in Cardiology},
doi = {10.1007/s00392-025-02719-z},
url = {https://doi.org/10.1007/s00392-025-02719-z}
}RIS
TY - JOUR TI - Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies AU - Klaus G. Parhofer AU - David Pittrow AU - Andreas L. Birkenfeld AU - Uwe Fraass AU - Bernd Hohenstein AU - Carsten Siegert AU - Jens Klotsche AU - Elisabeth Steinhagen-Thiessen AU - Stefan Dexl AU - Volker J. J. Schettler AU - Ulrich Laufs PY - 2025 JO - Clinical Research in Cardiology DO - 10.1007/s00392-025-02719-z UR - https://doi.org/10.1007/s00392-025-02719-z ER -
APA
Parhofer, K. G., Pittrow, D., Birkenfeld, A. L., Fraass, U., Hohenstein, B., Siegert, C., Klotsche, J., Steinhagen-Thiessen, E., Dexl, S., Schettler, V. J. J., & Laufs, U. (2025). Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02719-z
Source records
- crossref · retrieved 2026-09-26T17:35:57.402Z